Overview

Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine if rapamycin reduced angiomyolipomata volume in patients with tuberous sclerosis complex or lam.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborators:
The LAM Foundation
Tuberous Sclerosis Alliance
Treatments:
Everolimus
Sirolimus